# Obstructive Nephropathy: Imaging Modalities, Diagnostic Pitfalls, and Management

**Teaching Audience:** Experienced clinicians (internists, nephrologists, urologists, ER physicians) **Purpose:** Decision-making guide for imaging selection, interpretation of results, and evidence-based management **Last Updated:** 2026-02-28

------------------------------------------------------------------------

## 1. Pathophysiology of Obstructive Acute Kidney Injury

### Mechanism of Obstruction-Induced AKI

Obstruction of the urinary tract causes renal injury through several interconnected mechanisms:^([14](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-14))

1.  **Increased intraluminal pressure** → retrograde transmission to Bowman’s capsule → reduces GFR
2.  **Vasoconstriction** → increased renal vascular resistance (initially mediated by prostaglandins/NO, then RAS activation)
3.  **Tubular dysfunction** → altered reabsorption and secretion
4.  **Interstitial edema and inflammation** → ongoing fibrosis if obstruction persists
5.  **Activation of complement and cytokine cascade** → sterile inflammation

**Timeline:** Acute obstruction typically causes measurable GFR decline within hours. Pressure normalization is rapid after relief (minutes to hours), but functional recovery may lag by days to weeks.

### Acute vs. Chronic Obstruction

| Feature | Acute Obstruction | Chronic Obstruction |
|----|----|----|
| Duration | \<7 days (typical) | \>7 days |
| Renal ultrasound | Mild/moderate hydronephrosis | May have NO hydronephrosis (fibrosed system) |
| Creatinine recovery | Often rapid (24-72h) | Slower; may not recover fully |
| Histology | Tubular injury, minimal fibrosis | Tubular atrophy, extensive interstitial fibrosis |
| Post-obstructive diuresis | Common, often exuberant | Minimal |
| Reversibility | Excellent if \<7 days | Irreversible if \>6-12 weeks |

**Clinical Pearl:** Do not equate hydronephrosis with acute obstruction. Chronic high-grade obstruction can exist without dilated collecting system.

### Unilateral vs. Bilateral Obstruction

- **Unilateral obstruction** → usually does NOT cause AKI (compensatory hyperfiltration of contralateral kidney)
- **Bilateral obstruction** → causes AKI (both kidneys affected) or **AKI in solitary kidney** (functional obstruction in single functional unit)
- **Clinical implication:** Absence of AKI does not rule out unilateral obstruction; serial creatinine may appear stable while renal function is actually declining

### Complete vs. Partial Obstruction

- **Complete obstruction** → anuria or severe oliguria, rapid Cr rise
- **Partial obstruction** → may present with minimal Cr elevation, preserved urine output
  - **Danger:** Partial obstruction is easily missed on clinical grounds alone
  - Progressive slow obstruction (e.g., malignancy, strictures) may not trigger alarm until advanced

### Post-Obstructive Diuresis: Mechanism and Management

**Definition:** Excessive urine output (often \>200 mL/h) following relief of obstruction.^([12](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-12))

#### Pathophysiology

1.  **Osmotic component** (~30%): Retained urea, creatinine, phosphate act as osmotic diuretics
2.  **Aquaporin dysregulation** (~30%): Impaired water channel expression during obstruction; gradual recovery
3.  **Natriuresis** (~40%): Suppressed reabsorption in proximal tubule and thick ascending limb; blunted tubuloglomerular feedback
4.  **Increased ANP/BNP** from atrial stretch during volume expansion

#### Management of Post-Obstructive Diuresis

**Goal:** Maintain euvolemia while preventing electrolyte catastrophes.

1.  **Volume replacement strategy:**
    - Replace **50–75% of measured urine output** with 0.9% NaCl (or equivalent)
    - Do NOT replaces 100% (will perpetuate diuresis)
    - Do NOT restrict fluids completely (risks dehydration and Cr rebound)
2.  **Monitoring protocol:**
    - **Electrolytes:** Check q6h for first 24h (sodium, potassium, phosphate, magnesium, calcium)
    - **Creatinine:** q6–12h initially; assess rate of decline
    - **Urine output:** q1h for first 6h, then q2–4h
    - **Weight:** daily
    - **CVP/JVP:** assess volume status clinically
3.  **Expected electrolyte patterns:**
    - **Hyponatremia** (from dilute urine + hypotonic replacement)
    - **Hypokalemia** (from urinary wasting and alkalosis from contraction)
    - **Hypophosphatemia, hypomagnesemia** (urinary losses)
    - **Hypocalcemia** (from hyperphosphaturia during recovery)
4.  **Distinguishing pathologic from physiologic diuresis:**
    - **Physiologic:** Output declines as electrolytes normalize; patient improves clinically
    - **Pathologic:** Persistent high output \>200 mL/h beyond 48h despite adequate replacement; worsening electrolyte derangements; hemodynamic instability

    → In pathologic diuresis, consider desmopressin (vasopressin), but rare in modern practice.

------------------------------------------------------------------------

## 2. Renal Ultrasound: Capabilities and Limitations

Renal ultrasound is the first-line imaging modality for suspected obstruction due to portability, lack of radiation, and safety in renal failure. However, clinicians must understand its limitations to avoid diagnostic error.

### Diagnostic Accuracy

| Metric | Value |
|----|----|
| Sensitivity for hydronephrosis | 72–87% |
| Specificity for hydronephrosis | 73–83% |
| Sensitivity for detecting stone | 24–60% (depends on stone size, composition) |
| Positive predictive value (high-grade HD) | 90–95% |
| Negative predictive value | 70–80% (high false-negative rate) |

**Take-home:** A **negative US does NOT exclude obstruction.**^([1](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-1))

### What Ultrasound Does Well

1.  **Assesses kidney size and echogenicity**
    - Enlarged hyperechoic kidney suggests ATN or glomerulonephritis
    - Shrunken kidney suggests chronic kidney disease
2.  **Grades hydronephrosis severity** (subjective but clinically useful)
    - **Grade 0:** No hydronephrosis
    - **Grade 1 (mild):** Separation of renal sinus echoes only; no pelvic dilatation
    - **Grade 2 (moderate):** Pelvic dilatation; calyces dilated but maintaining convexity
    - **Grade 3 (severe):** Major calyces dilated and blunted; renal parenchyma compressed
3.  **Bladder assessment**
    - Post-void residual volume (PVR) suggests lower urinary tract obstruction
    - Bladder wall thickening indicates chronic outlet obstruction
4.  **Assesses for perinephric fluid** (suggests rupture of fornix)

### What Ultrasound Misses

#### 1. **Early Obstruction (\<24 hours)**

- Hydronephrosis requires time to develop (usually 6–24h for acute stone)
- Patient presenting with flank pain and normal US within 6h may have acute obstruction
- **Clinical strategy:** Repeat US or proceed to CT if high clinical suspicion and normal initial US

#### 2. **Dehydrated Patients**

- **Critical pitfall:** Hypovolemia reduces urine output; insufficient urine fails to dilate the collecting system
- Classic scenario: Patient with post-renal AKI, acute kidney injury from volume depletion, and normal US because urine flow is minimal
- Example: 70-year-old man with obstructing stone, sepsis, and dehydration—US shows no hydronephrosis; CT reveals complete obstruction
- **Lesson:** Low urine output ≠ reassurance of normal anatomy

#### 3. **Retroperitoneal Fibrosis**

- RF encases ureters **without dilating them** (encasing process prevents dilation despite obstruction)
- US appears normal
- **Diagnosis:** CT shows periaortic soft tissue mass
- **Incidence in AKI:** 0.3–1%, but underdiagnosed; always consider in bilateral hydronephrosis without obvious cause

#### 4. **Staghorn Calculi**

- Large calculi distort renal anatomy and mimic parenchymal disease
- Acoustic shadowing obscures detail
- Difficulty distinguishing obstruction from chronic pyelonephritis

#### 5. **Chronic Obstruction with Fibrosed Non-Dilated System**

- If obstruction develops slowly and chronically (e.g., ureteral stricture, malignancy), fibrosis may prevent pelvicalyceal dilation
- Kidney becomes atrophic, scarred, non-dilated
- **Clinical corollary:** Absence of hydronephrosis does not exclude long-standing obstruction
- **Functional consequence:** Non-dilated obstructed kidney has poor prognosis for recovery

#### 6. **Non-Dilated Obstructive Uropathy (NDOU)**

- Obstruction **without hydronephrosis** occurs in 4–8% of obstructive AKI cases^([2](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-2),[3](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-3))
- Mechanisms:
  - Acute presentation before hydronephrosis develops
  - Dehydration (reduced UOP)
  - Fibrosis preventing dilation
  - **Staghorn calculi** or **retroperitoneal fibrosis**
  - Peristaltic obstruction (e.g., retrocaval ureter, ureteral stricture)
- **Clinical challenge:** High suspicion required; CT mandatory if US negative

#### 7. **False Positives for Hydronephrosis**

- **Extrarenal pelvis:** Prominent renal pelvis draining into retroperitoneum; non-pathologic
- **Parapelvic cysts:** Cystic structures adjacent to renal pelvis; mimic calyceal dilatation
- **Pregnancy:** Dilation up to moderate grade right side (and left, less commonly) is physiologic due to hormonal (progesterone) effects and ureteral compression by gravid uterus
- **Full bladder:** High intravesical pressure transmitted retrograde; dilatation resolves post-void
- **Prominent renal sinus fat:** May be mistaken for dilated collecting system

### Resistive Index (RI)

**Definition:** RI = (Peak systolic velocity − End diastolic velocity) / Peak systolic velocity

**Values:** - Normal RI: \<0.60 (varies by age; increases slightly with age) - RI \>0.70: Suggests intrinsic renal disease or obstruction - RI \>0.80: Highly suspicious for obstruction

**Utility and limitations:** - **Sensitivity for obstruction:** 60–70% - **Specificity:** 70–80%^([4](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-4)) - **Confounders:** - Elevated RI in **acute tubular necrosis** (acute injury without obstruction) - Elevated RI in **chronic kidney disease** (fibrosis) - Elevated RI in **advanced age** (vascular stiffness) - Elevation in **systemic hypertension** (vascular resistance) - **Clinical bottom line:** RI is suggestive but not diagnostic; use as adjunct to morphologic findings

------------------------------------------------------------------------

## 3. CT Scan: When and Why

CT is superior to ultrasound for identifying the **level and cause of obstruction** and is mandatory when US is negative but clinical suspicion remains high.

### CT Without Contrast (Best for Stones)

**Sensitivity:** 91–97% for nephrolithiasis **Specificity:** 91–100%^([5](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-5),[6](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-6)) **Advantages:** - Gold standard for stone detection (95% of stones opaque) - Identifies stone location, size, density - Can estimate stone composition by Hounsfield units (HU): - Calcium oxalate/phosphate: 500–3000 HU - Uric acid: 200–400 HU - Cystine: 600–1100 HU - Drug crystals (indinavir, sulfadiazine): 100–200 HU

**Radiation exposure:** 5–10 mSv (equivalent to ~3 years background radiation)

**When mandatory:** - Suspicion of stone obstruction - US equivocal or negative with high pretest probability - Single kidney with anuria - Recurrent stone formers

### CT With IV Contrast (For Masses, Soft Tissue)

**Advantages:** - Superior for malignant obstruction (tumors, nodes) - Excellent for retroperitoneal fibrosis (periaortic soft tissue enhancement) - Identifies ureteral injuries, strictures - Opacifies collecting system and ureters - Can assess degree of renal perfusion

**Disadvantages:** - Contrast-induced nephropathy (CIN) risk - Adds ~10 mL iodinated contrast to imaging

**Use in AKI:** - **Baseline creatinine \<1.5 mg/dL:** Safe; prophylaxis usually not needed - **Creatinine 1.5–3.0 mg/dL:** Use iso-osmolar or low-osmolar contrast; hydrate IV - **Creatinine \>3.0 or on dialysis:** Discuss with radiology; often proceed with careful hydration; risk of CIN is lower than risk of missing diagnosis - **Diabetes + CKD:** Higher CIN risk; consider metformin washout, hydration

**Typical contrast volume:** 50–120 mL iodinated contrast

### Head-to-Head Comparison Table

| Feature | Ultrasound | Non-Contrast CT | Contrast-Enhanced CT |
|----|----|----|----|
| Sensitivity for hydronephrosis | 72–87% | 95–100% | 95–100% |
| Sensitivity for stones | 24–60% | 91–97% | 85–95% |
| Sensitivity for masses | 40–60% | 85–90% | 95%+ |
| Identifies obstruction level | Limited (distal) | Excellent | Excellent |
| Identifies obstruction cause | Limited | Good | Excellent |
| Radiation | None | 5–10 mSv | 5–10 mSv |
| Contrast agent | None | None | Iodinated IV |
| CIN risk | None | None | Yes (variable) |
| Cost | Low | Moderate | Moderate |
| Portability | Bedside capable | Radiology | Radiology |
| Safe in AKI | Yes | Yes | Cautious (see above) |
| Time to result | 5 min | 10–15 min | 15–20 min |

------------------------------------------------------------------------

## 4. Diuretic Renography (Lasix Renogram / MAG3 Scan)

### Clinical Role

Diuretic renography determines **functional significance of obstruction** in equivocal cases where anatomic findings (hydronephrosis) are present but obstruction is uncertain (e.g., dilated non-obstructed collecting system, UPJ obstruction, post-surgical follow-up).^([7](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-7))

### Imaging Agent and Protocol

**Most common agent:** Tc-99m MAG3 (mercaptoacetyltriglycine) - Agent is filtered and secreted by proximal tubule - Parallels effective renal plasma flow - Superior to DTPA in renal insufficiency (DTPA filtered only; accuracy declines if GFR \<30)

**Less common:** Tc-99m DTPA (diethylenetriaminepentaacetic acid) - Filtered by glomerulus only - Still acceptable; easier availability

**Protocol:** 1. Inject agent IV; begin imaging (typically anterior pelvic view) 2. Allow 20–30 min for agent uptake and excretion into collecting system 3. At peak filling, administer **furosemide 0.5–1.0 mg/kg IV** (typical dose 20–40 mg) 4. Continue imaging for another 20–30 min post-diuretic 5. Generate **renogram curve** showing activity over time in kidney/pelvis and bladder

### Interpretation

**Normal renogram pattern:** - Rapid uptake (seconds) - Peak activity at 3–5 min - Rapid washout after furosemide (T½ \<10 min = half-time to clear 50% of peak activity) - Curve returns to baseline by 20 min

**Dilatation categories:** 1. **Non-obstructed dilated collecting system** (“dilated non-obstructed” or DNU) - Pelvicalyceal dilatation present on imaging - Rapid washout after diuretic (T½ \<10 min) - Curve normalizes quickly - **Mechanism:** Capacious collecting system; not obstruction-induced but responds to diuretic

1.  **Indeterminate pattern**
    - T½ 10–20 min
    - Curve plateaus but may slowly decline with prolonged imaging
    - **Clinical significance:** Gray zone; functional significance unclear
    - **Management:** Consider delayed imaging, clinical context, repeat testing
2.  **Obstructed pattern**
    - T½ \>20 min
    - Curve continues rising or plateaus despite furosemide
    - No washout; activity persists in pelvis at 30 min
    - **Mechanism:** Anatomic or functional obstruction impeding urine flow

### Split Renal Function Assessment

Renography provides **differential renal function** (DRF): - Percentage contribution of each kidney to total GFR - Normal: Each kidney ~50%; asymmetry \<10% considered normal

**Clinical use:** - If obstructed kidney has DRF \<15%, interventional risk-benefit shifts toward observation - If DRF \>20%, intervention more likely to benefit function - If DRF \<10%, prognosis for recovery poor; palliative approach justified

### Limitations and Pitfalls

1.  **Dehydration:** Reduces urine output; poor tracer delivery; false-positive obstruction pattern
    - **Mitigation:** Ensure adequate IV hydration before test (250–500 mL NS)
2.  **Poor renal function (GFR \<30):**
    - DTPA becomes inaccurate (filtered only; poor clearance)
    - MAG3 preferred (secreted)
    - Even with MAG3, functional reserve minimal; curve interpretation difficult
3.  **Bladder outlet obstruction/high post-void residual:**
    - High intravesical pressure mimics upper tract obstruction
    - Catheterization or aggressive voiding may be needed
4.  **Hyperactivity in kidney from previous imaging with Tc-99m agents within 24h**
    - Request scheduling \>24h apart if possible
5.  **Technical limitations:**
    - Cannot visualize ureters well (activity washes out too quickly)
    - Limited anatomic detail (unlike CT/US)

### When to Order

- **Chronic hydronephrosis with uncertain obstruction:** Determine if truly obstructed or dilated non-obstructed
- **Unilateral hydronephrosis in pregnancy:** Differentiate physiologic from obstructive
- **UPJ/UVJ obstruction evaluation:** Quantify degree of obstruction; guide surgical decision-making
- **Recurrent pyelonephritis with hydronephrosis:** Assess if obstruction contributing
- **Post-surgical follow-up:** Serial assessment of split function and obstruction resolution

**Avoid ordering:** - Acute stone with normal renal function (diagnosis clear; focus on treatment) - Obvious bilateral obstruction (act first, no time for functional study) - Solitary obstructed kidney with anuria (intervention indicated regardless of function)

### Evidence Base

**Reference:** Society of Nuclear Medicine and Molecular Imaging (SNMMI) and European Association of Nuclear Medicine (EANM) *Practice Guideline for Diuretic Renal Scintigraphy* (2018)

------------------------------------------------------------------------

## 5. Retroperitoneal Fibrosis—Clinical Overview

*For comprehensive review, link to Retroperitoneal Fibrosis Comprehensive Review*

### Epidemiology and Presentation

- **Incidence:** 0.3–1 per 100,000 (rare but underdiagnosed)
- **Males \>\> Females** (3:1)
- **Peak age:** 50–70 years

### Pathophysiology

Idiopathic RF is mediated by **IgG4-positive plasma cells** in approximately 2/3 of cases (IgG4-related disease). Fibroblasts and myofibroblasts proliferate, encasing retroperitoneal structures (aorta, ureters, IVC, nerves).^([8](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-8),[9](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-9),[10](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-10))

### Imaging Presentation

**Ultrasound:** Often normal or shows hydronephrosis without obvious cause - May see periaortic echogenicity, but difficult to characterize

**CT findings:** - **Pathognomonic:** Periaortic (or paracaval) soft tissue mass - Encases aorta (“**aortic-hugging**” appearance) - Often bilateral ureteric involvement - Smooth, tapering ureteral narrowing - Medial displacement of ureters (fibrous tissue pulls ureters medially—diagnostic clue) - **Contrast enhancement:** Tissue enhances less than muscle - **Calcification:** Rare (unlike malignancy) - Relative sparing of kidneys unless advanced hydronephrosis

### Clinical Presentation in AKI Context

- **Bilateral hydronephrosis** with preserved renal size (no mass, no stone)
- **Elevated inflammatory markers:** ESR often \>100 mm/h, elevated CRP
- **Constitutional symptoms:** Dull flank/back pain, low-grade fever, malaise
- **No fever or dysuria** (not infection)
- May have systemic IgG4 involvement (pancreatitis, sialadenitis, thyroid)

### Differential Diagnosis

| Diagnosis | Key Differentiating Feature |
|----|----|
| Retroperitoneal fibrosis | Smooth periaortic mass, medial ureteral displacement, aorta “hugged,” often IgG4+ |
| Malignant nodes | Discrete heterogeneous nodes, history of malignancy, asymmetric involvement |
| Aortic aneurysm | Aortic dilation (\>3 cm), atherosclerotic features, contained rupture if symptomatic |
| Lymphoma | Bulky heterogeneous nodes, prior history, other nodal masses |

### Management Approach

1.  **Confirm diagnosis:** CT ± IgG4 testing, ESR/CRP, consider biopsy if atypical
2.  **Assess disease activity:** Inflammatory markers; imaging follow-up
3.  **Initiate immunosuppression (if confirmed IgG4-RF):**
    - Corticosteroids: Prednisone 1 mg/kg/day × 4 weeks, then taper
    - Response in 50–70%
    - Add azathioprine, mycophenolate, or rituximab if inadequate response
4.  **Manage obstruction:**
    - If severe AKI or anuria: ureteral stent or percutaneous nephrostomy
    - Most improve with medical therapy; stents often can be removed within 3–6 months

------------------------------------------------------------------------

## 6. Management of Obstructive AKI: Principles and Practice

### Deciding When to Intervene Emergently

**Absolute indications for immediate intervention (within hours):**

| Clinical Scenario | Rationale | Intervention |
|----|----|----|
| Bilateral obstruction | Both kidneys failing | Urgent relief needed |
| Solitary obstructed kidney | Single functional unit failing | Urgent relief needed |
| Sepsis/pyonephrosis + obstruction | Life-threatening infection | Emergent decompression + antibiotics |
| Anuria (nonresponsive to hydration) | Complete obstruction presumed | Urgent imaging + intervention if confirmed |

**Relative indications (consider in context of renal function trajectory):**

| Scenario | Decision Framework |
|----|----|
| Unilateral stone, stable Cr, normal contralateral function | Expectant management; monitor Cr/UOP q24h; intervene if Cr rises or UOP declines |
| Malignancy + bilateral obstruction, advanced cancer | Palliative approach; discuss goals; stent vs. comfort care |
| Single obstructed kidney, DRF \<10% | Poor prognosis for recovery; may not justify intervention risk |
| Pregnancy + symptomatic stone, recurrent UTI | May warrant intervention; risk-benefit discussion |

### Intervention Modalities

#### 1. **Ureteral Stent (JJ Stent)**

**Advantages:** - Minimally invasive (cystoscopy + fluoroscopy) - Maintains urothelium integrity - Can be placed emergently at bedside with portable equipment - Allows passage of urine around obstruction - Endoscopic removal simple

**Disadvantages:** - Stent encrustation risk (especially if prolonged \>4–6 weeks) - Biofilm formation (colonization by bacteria) - Risk of ureteral stricture with prolonged indwelling - Migration - Cannot be placed for complete ureteral transection or perforation

**Timing:** - Acute obstruction: place within 24–48h - Sepsis present: emergent placement

**Duration:** - Acute stone: 2–6 weeks (depends on expulsion likelihood) - Ureteral stricture: months to years; periodic replacement - Pregnancy: remove 4–6 weeks post-partum

#### 2. **Percutaneous Nephrostomy (PCN)**

**Advantages:** - Direct decompression; can be placed from CT/ultrasound - Allows drainage tube inspection (assess output quality) - Monitoring of urine output directly - Can obtain urine culture; assess for infection - Can inject contrast to visualize anatomy (antegrade pyelogram) - Can attempt percutaneous stone extraction

**Disadvantages:** - Requires interventional radiology (not immediately available in all settings) - External catheter; risk of dislodgment, accidental removal - Infection risk (pyelonephritis, sepsis) - Chronic drainage causes significant morbidity - Difficult conversion to ureteral stent if needed

**When preferred:** - **Pyonephrosis/sepsis:** Allows direct monitoring and drainage of infected urine - **Complete ureteral obstruction from stone/stricture when stent placement not possible** - **Need for diagnostic antegrade imaging** - **Anticipated prolonged drainage** (malignancy, stricture)

#### 3. **Combination Approach**

Some high-acuity scenarios warrant both: - **PCN for emergent drainage** (especially if septic) - **Subsequent stent placement for definitive management** after infection controlled and function stabilized

### Post-Intervention Monitoring

**First 24 hours:** - Assess urine output q1–2h (expect increased urine flow) - Check electrolytes q6h - Monitor temperature (assess for fever from pyelonephritis) - Check creatinine at 24h

**Ongoing (days 2–7):** - Serum creatinine daily until stable - Electrolytes daily - Urine output daily - Assess post-void residual (if stent placed) at 24–48h

**Key endpoints:** - Creatinine decline/stabilization (expect 10–20% daily improvement if no other renal disease) - Resolution of post-obstructive diuresis (output normalizes) - Electrolytes normalized - Patient afebrile, hemodynamically stable

### Specific Scenarios

#### Obstructing Nephrolithiasis

**Management algorithm:**

    Acute stone obstruction
       ↓
    US or CT confirms stone + obstruction
       ↓
    Assess: Cr, fever, sepsis, UOP, pain
       ↓
       ├─ Afebrile, no sepsis, normal/mildly elevated Cr, nonoliguric
       │  → Expectant management (hydration, pain control) + monitoring
       │     Intervention if: Cr rises >25% from baseline, UOP declines, fever develops
       │
       └─ Fever, sepsis, or rapidly rising Cr, anuria
          → Emergent intervention (stent or PCN)

**Recovery after stone passage:** - Most patients recover creatinine within 3–7 days - If recovery delayed (Cr not declining by day 5–7), reassess for: - Persistent obstruction (imaging repeated) - Secondary ATN (sepsis, hypotension) - Unrelated AKI etiology

#### Malignant Obstruction

**Goals:** Palliate symptoms; discuss life expectancy and morbidity

**Scenarios:** - **Early-stage cancer + bilateral obstruction:** Stent placement can bridge to chemotherapy/radiation - **Advanced stage + short expected survival:** Observe; intervene only if symptomatic (flank pain, fever) - **Mixed scenario (one kidney obstructed, other functioning):** Usually no intervention needed (unilateral; other kidney compensates)

**Prognosis:** Malignant obstruction carries poor renal prognosis; many patients progress to end-stage renal disease regardless of intervention

#### Obstruction in Pregnancy

**Physiologic hydronephrosis:** - Present in approximately 80% of pregnancies^([11](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-11)) - Progesterone-mediated (smooth muscle relaxation, decreased peristalsis) - Mechanical compression by gravid uterus (especially right side) - Usually mild to moderate; left side worse in third trimester (gravid uterus rotates)

**Distinguishing obstructive from physiologic:** - **Symptoms:** Pyuria, fever, flank pain suggest infection/obstruction - **Imaging:** If symptomatic, US or non-contrast CT (abdomen/pelvis protocol safe) - **Management:** Asymptomatic hydronephrosis—observe; symptomatic → consider stent vs. PCN

------------------------------------------------------------------------

## 7. Special Scenarios and Clinical Pearls

### Neurogenic Bladder and Outlet Obstruction

**Mechanism:** Impaired bladder emptying → elevated intravesical pressure → retrograde transmission to kidneys

**Common causes:** Spinal cord injury, multiple sclerosis, Parkinson’s disease, diabetes (neurogenic complications)

**Imaging findings:** - Bilateral hydronephrosis (may be non-dilated if fibrosis) - Thick-walled bladder - Elevated post-void residual (\>50 mL pathologic)

**Management:** - Clean intermittent self-catheterization (CISC) most important intervention - Anticholinergics (oxybutynin) to reduce detrusor hyperreflexia - Prophylactic antibiotics (long-term colonization near-universal) - Monitor renal function annually; imaging as needed

### Benign Prostatic Hyperplasia (BPH) and Urethral Stricture

**BPH-induced obstruction:** - More common in elderly men - Insidious onset; gradual creatinine decline may not trigger concern - Reduced stream, nocturia, incomplete emptying

**Diagnosis:** - Elevated PVR on US - Cystoscopy shows enlarged prostate (not needed for diagnosis in AKI workup)

**Management:** Alpha-blocker (tamsulosin, doxazosin) ± 5-alpha reductase inhibitor (finasteride) - If inadequate response: transurethral resection of prostate (TURP)

**Urethral stricture:** - Etiology: prior trauma, instrumentation, lichen sclerosus, gonococcal urethritis - Diagnosis: retrograde urethrography or cystoscopy - Management: direct visual internal urethrotomy (DVIU) or urethroplasty

### Pelvic Malignancy

**Cancers causing obstruction:** Prostate, bladder, colorectal, ovarian, uterine

**Imaging findings vary** by tumor type but may include: - Mass encasing ureter - Lymphadenopathy compressing ureter - Bladder wall infiltration - Unilateral or bilateral obstruction

**Considerations:** - Prior oncologic history (recurrence vs. new primary) - Extent of disease (CT staging) - Prognosis (inform intervention decision)

------------------------------------------------------------------------

## 8. Integration: Diagnostic Algorithm for Suspected Obstruction

    Suspected obstructive AKI
    │
    ├─ Step 1: Clinical assessment
    │  ├─ History: flank pain, anuria, prior obstruction, malignancy, retention
    │  ├─ Exam: CVA tenderness, palpable bladder, fever (pyonephrosis?)
    │  └─ Labs: urine sediment, urine culture, electrolytes, creatinine
    │
    ├─ Step 2: Bedside renal ultrasound
    │  ├─ Hydronephrosis present?
    │  │  ├─ YES → Proceed to Step 3
    │  │  └─ NO → Go to Step 2B
    │  │
    │  └─ Step 2B: Assess probability
    │     ├─ LOW probability (stable Cr, normal exam, no risk factors) → STOP; consider other etiologies
    │     ├─ HIGH probability (anuria, severe AKI, risk for obstruction) → Proceed to Step 3
    │     └─ INTERMEDIATE → Repeat US or proceed to CT
    │
    ├─ Step 3: Determine severity and urgency
    │  ├─ Sepsis/fever? → EMERGENT intervention (stent/PCN)
    │  ├─ Bilateral obstruction? → URGENT intervention (within 24h)
    │  ├─ Solitary obstructed kidney? → URGENT intervention
    │  ├─ Unilateral, stable Cr, afebrile → EXPECTANT (monitor, intervene if Cr rises)
    │  └─ Anuria nonresponsive to hydration? → URGENT imaging + intervention if confirmed
    │
    ├─ Step 4: Identify etiology (imaging modality)
    │  ├─ Suspected stone → Non-contrast CT (gold standard)
    │  ├─ Suspected mass/retroperitoneal pathology → Contrast CT ± MRI
    │  ├─ Equivocal findings → CT if available; if unavailable, consider MRU
    │  └─ Functional significance needed (dilated non-obstructed?) → Renography
    │
    └─ Step 5: Intervention and follow-up
       ├─ Relief of obstruction (stent/PCN)
       ├─ Monitor post-obstructive diuresis (replace 50–75% UOP)
       ├─ Recheck Cr at 24–48h (assess recovery trajectory)
       ├─ Treat underlying cause (stone passage, stent removal, address malignancy, etc.)
       └─ Surveillance for recurrence/complications

------------------------------------------------------------------------

## 9. Red Flags and Diagnostic Pearls

| Red Flag | Implication | Action |
|----|----|----|
| Anuria + normal US | NDOU or severe dehydration | Repeat US, consider CT, assess volume status |
| Bilateral hydronephrosis + no stone/mass | Retroperitoneal fibrosis, node disease | CT with contrast; check IgG4, ESR |
| Fever + obstructing stone | Pyonephrosis (infected obstructed system) | EMERGENT PCN + antibiotics; life-threatening |
| Acute severe flank pain + normal US \<6h | Early obstruction before dilation | Repeat US at 12–24h or proceed to CT |
| Elevated RI (\>0.70) + dilated system | May suggest obstruction, but not diagnostic | Correlate clinically; consider renography if equivocal |
| Unilateral obstruction + stable Cr | Do NOT falsely reassure; verify contralateral function | Renal scan (MAG3) to assess split function |
| Post-obstructive diuresis + worsening hypokalemia despite replacement | Pathologic diuresis (rare) or refeeding phenomenon | Add K+ supplementation; consider desmopressin if severe |

------------------------------------------------------------------------

## 10. Clinical Vignettes: Applying the Framework

### Vignette 1: Acute Stone Obstruction in Nonoliguric Patient

**Presentation:** 68-year-old man with history of recurrent kidney stones presents with right flank pain × 6 hours. Creatinine 1.1 (baseline 0.9), urine output 1.5 L in 6 hours. Afebrile, hemodynamically stable.

**Imaging:** US shows right hydronephrosis grade 2; no left-sided findings.

**Decision:** - Unilateral obstruction → no AKI (contralateral kidney is functioning) - Afebrile, nonoliguric, minimal Cr elevation - **Management:** Expectant; hydrate, pain control, monitor Cr daily, check UOP - **Intervention threshold:** If Cr rises \>25% from baseline OR urine output declines OR fever develops

**Expected course:** Stone passes within 2–4 weeks; Cr returns to baseline; no intervention needed

------------------------------------------------------------------------

### Vignette 2: Bilateral Obstruction with Sepsis

**Presentation:** 52-year-old woman with history of recurrent strictures (prior ureteral surgery) presents with fever (39.2°C), flank pain, and nausea × 24 hours. Creatinine 2.8 (baseline 1.1), oliguria (UOP 400 mL/24h), WBC 14,000, lactate 2.5.

**Imaging:** US shows bilateral hydronephrosis grade 3; bladder normal.

**Decision:** - Bilateral obstruction + sepsis = **LIFE-THREATENING** - **Immediate action:** 1. Broad-spectrum antibiotics (meropenem + vancomycin until culture results) 2. Fluid resuscitation 3. Emergent bilateral PCN placement (or stent if immediate cystoscopy available)

**Expected course:** Fever resolves within 24–48h of decompression; creatinine declines over next 3–5 days; source identified (stricture documented on antegrade imaging); definitive management (redo ureteral surgery, stent exchange) planned once stable

------------------------------------------------------------------------

### Vignette 3: Bilateral Hydronephrosis, No Obstruction on Imaging

**Presentation:** 71-year-old man with prostate cancer (metastatic to bone) presents with creatinine elevation (2.2, baseline 1.0). Imaging shows bilateral hydronephrosis. CT with contrast shows **NO mass, NO nodes, NO stone**, but periaortic soft tissue prominence.

**Labs:** ESR 102, CRP 8.5, IgG4 elevated (95 mg/dL; normal \<135 but suspicious)

**Decision:** - Suspect **retroperitoneal fibrosis** (IgG4-related disease) - **Confirmatory steps:** 1. Consider biopsy (periaortic tissue) if diagnosis uncertain 2. Check systemic IgG4 involvement (pancreas, salivary glands) 3. Rheumatology/pathology consultation - **Initial management:** 1. Place ureteral stent(s) or PCN for acute decompression 2. Start corticosteroids (prednisone 1 mg/kg/day) 3. Plan repeat imaging in 4–6 weeks to assess response

**Expected course:** With steroid therapy, 50–70% show significant improvement in obstruction within 3–6 months; stents can often be removed; long-term remission possible with immunosuppression

------------------------------------------------------------------------

### Vignette 4: Non-Dilated Obstructive Uropathy

**Presentation:** 44-year-old woman with anuria × 2 hours post-cesarean delivery for preeclampsia. Creatinine 1.8 (pre-delivery 0.7). **US: normal kidneys, no hydronephrosis**, normal bladder.

**Clinical context:** Intra-operative note mentions possible ureteral injury.

**Decision:** - **NDOU suspected** (acute ureteral injury, insufficient time for hydronephrosis to develop) - **Imaging:** Non-contrast CT abdomen/pelvis → shows urinoma, ureteral extravasation - **Management:** 1. Emergent urology/surgery consultation 2. PCN placement for drainage 3. Surgical re-exploration ± ureteral repair depending on delay and degree of injury

------------------------------------------------------------------------

## 11. Key Takeaways for Clinicians

1.  **Do NOT trust negative ultrasound to exclude obstruction.** NDOU occurs in 4–8% of obstructive AKI. High clinical suspicion warrants CT.

2.  **Dehydration is the enemy of US.** Hypovolemia reduces urine output; insufficient urine fails to dilate the collecting system. May present with normal US despite complete obstruction.

3.  **Bilateral obstruction is a medical emergency.** Even mild symptoms warrant urgent intervention. Sepsis + obstruction = life-threatening.

4.  **Unilateral obstruction rarely causes AKI** (assuming contralateral kidney intact). Monitor but do not necessarily rush to intervention in hemodynamically stable, afebrile patient.

5.  **Non-contrast CT is the gold standard for stone** (91–97% sensitivity). If stone suspected, CT is the appropriate test.

6.  **Retroperitoneal fibrosis is underdiagnosed.** Think of it in bilateral hydronephrosis without obvious stone/mass. CT appearance is diagnostic (periaortic soft tissue).

7.  **Post-obstructive diuresis is common and self-limited** (physiologic). Replace 50–75% of urine output, not 100%. Monitor electrolytes q6h. Pathologic diuresis is rare.

8.  **Diuretic renography has limited role in acute AKI** but is valuable for determining functional significance in equivocal chronic cases.

9.  **Sepsis + obstruction = PCN preferred** (emergent drainage, allows monitoring of infected urine). Stent for hemodynamically stable with no infection.^([13](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html#ref-13))

10. **Treatment of underlying cause is critical.** Relief of obstruction alone is insufficient; address stone passage, stricture, malignancy, or fibrosis.

------------------------------------------------------------------------

### Sources

1.  Smith-Bindman R, Aubin C, Bailitz J, et al. Ultrasonography versus computed tomography for suspected nephrolithiasis. *N Engl J Med*. 2014;371(12):1100–1110. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25229916/)
2.  Feliciangeli V, Noce A, Montalto G, Germani S, Miano R, Asimakopoulos AD. Non-dilated obstructive nephropathy. *Clin Kidney J*. 2024;17(10):sfae287. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39391590/)
3.  Onuigbo MA, Agbasi N. Non-dilated obstructive uropathy — an unrecognized cause of acute renal failure in hospitalized US patients: three case reports seen over 6 months in a northwestern Wisconsin nephrology practice. *Ren Fail*. 2010;32(9):1106–1110. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20954986/)
4.  Tublin ME, Dodd GD 3rd, Verdile VP. Acute renal colic: diagnosis with duplex Doppler US. *Radiology*. 1994;193(3):697–701. [PubMed](https://pubmed.ncbi.nlm.nih.gov/7972809/)
5.  Smith RC, Verga M, McCarthy S, Rosenfield AT. Diagnosis of acute flank pain: value of unenhanced helical CT. *AJR Am J Roentgenol*. 1996;166(1):97–101. [PubMed](https://pubmed.ncbi.nlm.nih.gov/8571915/)
6.  Türk C, Petřík A, Sarica K, et al. EAU guidelines on diagnosis and conservative management of urolithiasis. *Eur Urol*. 2016;69(3):468–474. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26318710/)
7.  Taylor AT, Brandon DC, de Palma D, et al. SNMMI procedure standard/EANM practice guideline for diuretic renal scintigraphy in adults with suspected upper urinary tract obstruction 1.0. *Semin Nucl Med*. 2018;48(4):377–390. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29852947/)
8.  Vaglio A, Peyronel F, Bajema IM, Pegoraro F. Retroperitoneal fibrosis. *Lancet*. 2026. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41905382/)
9.  Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. *J Am Soc Nephrol*. 2016;27(7):1880–1889. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26860343/)
10. Katz G, Stone JH. Clinical perspectives on IgG4-related disease and its classification. *Annu Rev Med*. 2022;73:545–562. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34669430/)
11. Rasmussen PE, Nielsen FR. Hydronephrosis during pregnancy: a literature survey. *Eur J Obstet Gynecol Reprod Biol*. 1988;27(3):249–259. [PubMed](https://pubmed.ncbi.nlm.nih.gov/3280355/)
12. Baum N, Anhalt M, Carlton CE Jr, Scott R Jr. Post-obstructive diuresis. *J Urol*. 1975;114(1):53–56. [PubMed](https://pubmed.ncbi.nlm.nih.gov/1142500/)
13. Ramsey S, Robertson A, Ablett MJ, Meddings RN, Hollins GW, Little B. Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. *J Endourol*. 2010;24(2):185–189. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20063999/)
14. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract*. 2012;120(4):c179–c184. [PubMed](https://pubmed.ncbi.nlm.nih.gov/22890468/)

## Related Resources and Cross-References

- Comprehensive AKI Evaluation and Differential Diagnosis
- Prerenal AKI, Cardiorenal, and Hepatorenal Syndromes
- Acute Tubular Necrosis: Intrinsic and Extrinsic Forms
- Acute Interstitial Nephritis: Drug-Induced and Infectious
- Non-Dilated Obstructive Uropathy (NDOU)
- Retroperitoneal Fibrosis: Comprehensive Review
- AKI Staging and Classification (KDIGO)
- ← Back to AKI Hub

------------------------------------------------------------------------

**Document Version:** 1.0 **Author:** Nephrology clinical teaching series **Last Reviewed:** 2026-02-28 **Next Review:** 2027-02-28


---

[Website version](https://urinenephrology.org/mastery/aki-advanced/obstructive-nephropathy-imaging-review.html) · Markdown synchronized October 3, 2026.